|
Active substance |
ramucirumab |
|
Holder |
S.A. Eli Lilly N.V. Belgium |
|
Status |
Closed |
|
Indication |
treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with systemic therapy |
|
Public documents |
|
|
Last update |
19/04/2021 |
Cyramza®
Last updated on 10/09/2024